Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida, 32224, USA.
J Hematol Oncol. 2010 Oct 27;3:42. doi: 10.1186/1756-8722-3-42.
Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainly due to the lack of molecular targets, little progress has been made in the treatment of patients with triple-negative breast cancer. Recent improved understanding of the natural history, pathophysiology, and molecular features of triple-negative breast cancers have provided new insights into management and therapeutic strategies for women affected with this entity. Ongoing and planned translational clinical trials are likely to optimize and improve treatment of women with this disease.
乳腺癌是一种异质性疾病，由不同的亚型组成，其特点是临床病理特征、预后和对治疗的反应不同。在过去的十年中，在治疗对激素治疗敏感的乳腺癌以及恶性细胞过表达或扩增 HER2 的患者方面取得了重大进展。相比之下，由于缺乏分子靶点，三阴性乳腺癌患者的治疗进展甚微。最近对三阴性乳腺癌的自然史、病理生理学和分子特征的认识的提高，为患有这种疾病的女性的管理和治疗策略提供了新的见解。正在进行和计划中的转化临床研究可能会优化和改善对这种疾病患者的治疗。
